Equity Research

INC Research Holdings, Inc.

INCR: Q4 2014 Earnings Full Analysis

- What to do from here. INCR has strong momentum following its first quarter as a public company. Revenue, EPS, and bookings all beat consensus, and the company issued 2015 guidance with a mid-point slightly above our prior estimate on EPS and in-line with our prior estimate on revenue, despite substantial FX revenue headwinds (the FX impact on operating income is neutral due to a large cost base in GBP). With a conservative coverage ratio (89%), the outlook for continued double-digit revenue growth and 20%+ EPS growth seems realistic, which we believe makes the current valuation look reasonable, if not attractive. We are raising our valuation range to \$32-34 from \$29-30 and increasing our 2015E EPS to \$1.22 from \$1.20. Establishing our 2016E EPS of \$1.50.
- **Thoughts on Astellas.** We believe some investors are concerned about the company's relationship with Astellas, which provided 12% of revenue in 2014. The original relationship was an FSP contract with a renewal date in Q2 2015, which INCR believes could be renewed under a full service model. The company indicates negotiations are going well but that some of the conservatism built into guidance is due to risk-adjusting of Astellas. We think Astellas will indeed be renewed, but we also appreciate the company's more conservative guidance, and we think a renewal of the contract could create upside potential to our current estimates.
- Financial highlights. Revenue of \$214MM beat consensus of \$208MM and our estimate of \$209MM. EPS of \$0.25 (including stock comp) beat our estimate of \$0.21 (recall that we include stock comp, which the company excludes from its own non-GAAP number, making consensus EPS somewhat unreliable due to a mixed basis). Book-to-bill of 1.48x beat our estimate of 1.20x. Besides the revenue beat, a strong operating margin (15.9% versus our 15.3% estimate) helped drive the EPS beat. FX played a large factor in the margin beat as the company has more costs in GBP than revenue.
- **Guidance highlights.** The company issued 2015 EPS guidance of \$1.19-1.29 on revenue of \$870-900MM. EPS guidance excludes about \$0.04 of stock-based comp, so on an apples-to-apples basis with our methodology, the EPS guidance would be \$1.15-1.25. The revenue guidance assumes an FX headwind of about 400 bps, although FX should be neutral on operating income. Management indicates the current backlog covers 89% of 2015 revenue guidance, which compares favorably to other companies that give this metric.

Valuation Range: \$32.00 to \$34.00 from \$29.00 to \$30.00

Our valuation range is DCF-based (WACC = 8.5%; terminal NOPLAT growth = 2%) and represents 22x our 2016 EPS estimate. Risks include: (1) project cancellations or delays due to client M&A, economic weakness, pipeline reprioritization, or compound failure; (2) a reversal in the trend toward increased outsourcing; (3) regulatory risks;(4) limited track record in public equity markets; and (5) controlled company status.

Investment Thesis:

We believe INCR should be able to grow revenue and EPS at a CAGR of about 10% and 20%, respectively, over the next few years. While we also expect higher-than-average bookings volatility, we believe the strong growth potential tilts the risk/reward profile in a favorable direction.

Please see page 4 for rating definitions, important disclosures and required analyst certifications
All estimates/forecasts are as of 02/24/15 unless otherwise stated.

Wells Fargo Securities, LLC does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of the report and investors should consider this report as only a single factor in making their investment decision.



Outperform / V

Sector: Pharmaceutical Services
Overweight

Earnings Estimates Revised Up

	2014A	2015	E	2016E			
EPS		Curr.	Prior	Curr.	Prior		
Q1 (Mar.)	\$0.11	\$0.28	NC	\$0.35			
Q2 (June)	0.26	0.29	0.28	0.36			
Q3 (Sep.)	0.27	0.31	NC	0.38			
Q4 (Dec.)	0.25	0.33	0.32	0.40			
FY	\$0.89	\$1.22	1.20	\$1.50			
CY	\$0.89	\$1.22		\$1.50			
FY P/EPS	31.4x	22.9x		18.6x			
Rev.(MM)	\$810	\$891		\$1,000			

Source: Company Data, Wells Fargo Securities, LLC estimates, and Reuters
NA = Not Available, NC = No Change, NE = No Estimate, NM = Not Meaningful
V = Volatile, N = Company is on the Priority Stock List

Non-GAAP EPS excludes amortization of intangibles and non-recurring items.

Ticker	INCR
Price (02/24/2015)	\$27.91
52-Week Range:	\$19-29
Shares Outstanding: (MM)	61.3
Market Cap.: (MM)	\$1,710.9
S&P 500:	2,113.79
Avg. Daily Vol.:	106,661
Dividend/Yield:	\$0.00/0.0%
LT Debt: (MM)	\$420.0
LT Debt/Total Cap.:	52.0%
ROE:	34.0%
3-5 Yr. Est. Growth Rate:	21.0%
CY 2015 Est. P/EPS-to-Growth:	1.1x
Last Reporting Date:	02/24/2015

Source: Company Data, Wells Fargo Securities, LLC estimates, and Reuters

Tim Evans, Senior Analyst (212) 214-8010

tim.evans@wellsfargo.com Luke E. Sergott, Associate Analyst

(212) 214-8027 luke.sergott@wellsfargo.com

Together we'll go far



Exhibit 1. Variance Table

FY ending December	Actual		Est	Actual	Cons	Yr / Yr	Seq
In millions except EPS	Q4 2013	Q3 2014	Q4 2014	Q4 2014	Q4 2014	change	change
Total revenues	\$ 174	\$ 208	\$ 209	\$ 214	\$ 208	22.6%	2.9%
Cost of revenues	112	130	134	134		19.5%	3.4%
Gross profit	62	78	75	80		28.1%	2.0%
Selling, general & administrative	34	38	38	41		19.9%	8.0%
Depreciation	5	5	5	<u>5</u>		(4.8%)	5.4%
Operating income	23	36	32	34		47.6%	(4.8%)
Interest expense and other, net	<u> 16</u>	13	12	<u>11</u>		(30.8%)	(13.5%)
Pretax income	7	23	20	23		231.0%	0.2%
Provision for income taxes	3	8	8	<u>8</u>		232.6%	0.1%
Income before equity in affiliates	4	14	\$ 13	\$ 14		230.1%	0.2%
Non-GAAP EPS	0.08	\$ 0.27	\$ 0.21	\$ 0.25		192.0%	(10.5%)
Non-GAAP EPS (company method)	0.10	\$ 0.28	\$ 0.22	\$ 0.26		152.7%	(8.8%)
Diluted shares outstanding	52	53	61	59			
EBITDA	\$ 28	\$ 40	\$ 37	\$ 39		37.9%	(3.6%)
MARGIN ANALYSIS							
Cost of revenue	64.3%	62.4%	64.2%	62.7%		(160) bps	30 bps
Gross margin	35.7%	37.6%	35.8%	37.3%		160 bps	(30) bps
SG&A / revenue	19.5%	18.2%	18.1%	19.1%		(40) bps	90 bps
Depreciation / revenue	3.0%	2.3%	2.4%	2.3%		(70) bps	10 bps
Operating margin	13.2%	17.2%	15.3%	15.9%		270 bps	(130) bps
Tax rate	36.8%	37.0%	37.0%	36.9%		20 bps	0 bps
Net margin	2.5%	6.9%	6.2%	6.7%		420 bps	(20) bps
EBITDA margin	16.2%	19.5%	17.7%	18.2%		200 bps	(120) bps
REVENUE ANALYSIS							
Total revenues	\$ 174	\$ 208	\$ 209	\$ 214			
Growth: core	14.0%	22.7%	21.5%	24.9%			
Growth: FX	0.6%	(0.2%)	(2.3%)	(2.7%)			
Growth: acquisitions	<u>0.0%</u>	<u>0.4%</u>	<u>0.4%</u>	<u>0.4%</u>			
Growth: total	14.6%	22.9%	19.6%	22.6%			
Beginning backlog	\$ 1,373	\$ 1,493	\$ 1,506	\$ 1,506			
Revenue	(174)	(208)	(209)	(214)			
Net bookings	285	249	250	316	260	10.9%	26.9%
Other adjustments	7	(28)	(7)	(20)			
Ending backlog	\$ 1,491	\$ 1,506	\$ 1,541	1589	1,550		
Net book-to-bill	1.64	1.20	1.20	1.48			
Backlog burn rate	12.7%	13.9%	13.9%	14.2%			

Source: FactSet; Company data; Wells Fargo Securities, LLC estimates

Exhibit 3. Earnings Model


10	In millions, except per share															
solf or evenues	INCOME STATEMENT	2011	2012	2013	Q1	Q2	Q3	Q4	2014	Q1E	Q2E	Q3E	Q4E	2015E	2016E	2017E
and of revenues 280 389 392 121 131 130 134 515 132 131 144 148 570 540 705 Cross prefit 15	Total revenues	\$ 437	\$ 579	\$ 652	\$ 185	\$ 204	\$ 208	\$ 214	\$ 810	\$ 214	\$ 220	\$ 226	\$ 232	\$ 891	\$ 1,000	\$ 1,106
Gross profit 157 190 220 64 73 78 80 295 77 79 82 84 231 361 402	Cost of revenues		389		121	131	130	134	515	137	141	144	148	570	640	705
percention 16 20 19 2 19 2 5 5 5 5 5 2 11 23 23 23 23 25 5 5 2 11 23 23 23 25 25 25 25 25 25 25 25 25 25 25 25 25	Gross profit				64	73	78		295	77	79	82		321		402
percention 16 20 19 2 19 2 5 5 5 5 5 2 11 23 23 23 23 25 5 5 2 11 23 23 23 25 25 25 25 25 25 25 25 25 25 25 25 25																
Operating income																
terest expense and other, net	1 .				25	3/				33						
Pretaix flormer laxes																
oversistic friscome taxes 2 1																
Met Income																
Der Grander PES																
an-GAAP PS (company method) \$ 0.005 \$ 0.31 \$ 0.12 \$ 0.21 \$ 0.22 \$ 0.26 \$ 0.03 \$ 0.09 \$ 0.30 \$ 0.32 \$ 0.34 \$ 1.26 \$ 1.54 \$ 1.81 \$,	_												1	
Made shares outstanding 43.9 52.2 52.0 51.9 52.2 52.5 58.8 53.9 51.5 63.7 63.8 63.8 63.8 63.8 64.3 65.1	Non-GAAP EPS															
BITDA S 6.3 S 80 S 103 S 32 S 39 S 40 S 39 S 151 S 38 S 40 S 42 S 43 S 162 S 186 S 210 MACRITY ANNUALYSIS MACRITY ANNUALYSI	Non-GAAP EPS (company method)	\$ (0.08)	\$ 0.05	\$ 0.31	\$ 0.12	\$ 0.27	\$ 0.28	\$ 0.26	\$ 0.93	\$ 0.29	\$ 0.30	\$ 0.32	\$ 0.34	\$ 1.26	\$ 1.54	\$ 1.81
BITDA S 6.3 S 80 S 103 S 32 S 39 S 40 S 39 S 151 S 38 S 40 S 42 S 43 S 162 S 186 S 210 MACRITY ANNUALYSIS MACRITY ANNUALYSI	Diluted shares outstanding	12.0	52.2	52 O	51.0	52.2	52 F	50 0	52.0	62.7	62.7	62.0	62.0	62.0	612	65.1
ALCHINALYSIS 64 0% 67.2% 66.3% 65.4% 64.3% 6.24% 6.27% 6.316% 64.1% 64.1% 63.6% 63.8% 63.8% 63.9% 56.7% Gross margin 70 0% 70 0% 71.2%	_															
set of revenue	EBITDA	\$ 63	\$ 80	\$ 103	\$ 32	\$ 39	\$ 40	\$ 39	\$ 151	\$ 38	\$ 40	\$ 42	\$ 43	\$ 162	\$ 186	\$ 210
Gross margin 36 0% 32.8% 33.7% 33.7% 34.6% 35.7% 37.6% 37.6% 37.6% 37.6% 39.8% 35.9% 36.2% 36.2% 36.1% 36.1% 36.1% 36.1% 36.4% procedation / revenue 3.6% 3.4% 2.9% 37.7% 2.5% 2.3% 2.3% 2.7% 2.3% 2.3% 2.3% 2.4% 2.3% 2.3% 2.3% 2.4% 16.7% 17.7% 17.2% 17.5% 17.5% 16.5% 16.2% 17.3% 16.5% 16.2% 17.3% 16.5% 16.2% 17.3% 16.5% 16.2% 17.3% 16.5% 16.2% 17.3% 17.3% 16.5% 16.2% 17.3% 17.3% 17.3% 17.3% 16.5% 16.2% 17.3% 17	MARGIN ANALYSIS															
2.8.A / revenue	Cost of revenue															
procedation / revenue 3 5 % 3 4 % 2 9 % 3 7 % 2 5 % 2 3 % 2 7 % 2 7 % 15 9 % 15 7 % 15 7 % 15 7 % 15 7 % 15 7 % 15 7 % 15 7 % 15 9 % 15 7 % 15	Gross margin	36.0%	32.8%	33.7%	34.6%	35.7%	37.6%	37.3%	36.4%	35.9%	35.9%	36.2%	36.2%	36.1%	36.1%	36.3%
Operating margin 10.7% 10.4% 12.9% 13.9% 16.8% 17.2% 15.9% 15.9% 15.9% 15.9% 16.1% 15.9% 16.8% 10.4% 18.9% 16.6% No.	SG&A / revenue	21.6%	18.9%	17.9%	17.3%	16.5%	18.2%	19.1%	17.8%	18.0%	17.9%	17.8%	17.7%	17.8%	17.5%	17.3%
Operating margin 10.7% 10.4% 12.9% 13.6% 16.8% 17.2% 15.9% 15.6% 15.7% 16.6% 16.7% 16.7%	Depreciation / revenue	3.6%	3.4%	2.9%	3.7%	2.5%	2.3%	2.3%	2.7%	2.3%	2.3%	2.3%	2.4%	2.3%	2.3%	2.4%
Met margin	Operating margin	10.7%	10.4%	12.9%	13.6%	16.8%	17.2%	15.9%	15.9%	15.6%	15.7%	16.1%	16.1%	15.9%	16.3%	16.6%
Met margin	Tax rate			36.9%				36.9%				36.0%				
## No. AMALYSIS NY / NP 14.3% 13.9% 13.9% 13.9% 17.4% 19.2% 19.5% 18.2% 18.6% 17.9% 18.0% 18.5% 18.5% 18.2% 18.6% 19.0% 14.3% 22.9% 23.3% 27.9% 22.9% 22.9% 22.9% 24.1% 15.7% 8.0% 8.7% 8.5% 10.1% 12.2% 10.6% 15.6% 6.7% 16.6% 18.7% 37.7% 19.9% 23.1% 20.0% 18.5% 4.5% 5.3% 0.1% 15.6% 6.7% 16.6% 18.2% 18.2% 18.6% 18.2%																
## AND CHANLYSIS VR / VR 22 5% 22	EBITDA margin															
Tall revnues 32.5 % 12.7 % 23.3 % 27.9 % 22.9 % 22.4 % 24.1 % 15.7 % 8.0 % 8.7 % 8.5 % 10.1 % 10.6 % Gross profit 20.9 % 15.8 % 42.2 % 38.0 % 23.8 % 20.0 % 8.5 % 4.5 % 5.3 % 5.3 % 5.3 % 5.3 % 5.3 % 16.0 % 6.7 % 16.8 % 18.7 % 37.7 % 19.9 % 22.1 % 20.0 % 17.1 % 6.5 % 6.5 % 6.5 % 6.5 % Operating income 28.9 % 38.8 % 90.5 % 73.8 % 27.3 % 47.0 % 63.7 % 32.9 % 1.2 % 10.6 % Operating income 28.9 % 38.8 % 90.5 % 73.8 % 27.3 % 47.0 % 63.7 % 32.9 % 1.2 % 1.6 % 10.2 % 9.9 % 15.2 % 12.2 % Net income NA 65.1 % NA 33.6 % 71.9 % 23.0 % 24.9 % 22.6 % 22.8 % 22.8 % 22.8 % 22.8 % 1.2 % 1.6 % 10.2 % 9.9 % 15.2 % 12.2 % Net income 19.1 % 10.4 % 10.1 % 10.2 % 10.0 % 11.2 % 10.6 % NA 65.7 % NA 33.6 % 71.9 % 23.0 % 24.9 % 22.6 % 22.8 % 22.8 % 22.8 % 22.8 % 12.8 % 10.0 % 12.2 % Na 10.4 % 10.1 % 10.2 % 10.0 % 10.2 % 10.0 % 10.0 % 10.0 % 10.0 % Na 67.7 % NA 33.6 % 71.9 % 23.0 % 24.9 % 22.6 % 22.8 % 22.		111010	101110	191910											1	
Gross profit 20,9% 15,8% 42,2% 38,0% 29,9% 28,1% 33,8% 20,0% 8,5% 4,5% 5,3% 9,1% 12,2% 11,3% 26,6% 11,0% 26,6% 37,8% 37,8% 37,7% 10,4% 20,6% 11,2% 31,0% 10,0% 20,0% 11,2% 31,0% 10,0% 20,0% 11,2% 31,0% 10,			22 50/	12 70/	22.20/	27.00/	22.00/	22.40/	24 10/	1E 70/	9.09/	0.70/	0 50/	10 19/	12 20/	10.69/
16.0% 6.7% 16.8% 18.7% 17.7% 19.9% 23.1% 23.1% 20.6% 17.1% 0.5% 17.1% 0.9% 0.7% 19.9% 0.9																
pereclation																
Departing income 28,9% 38,8% 90,5% 73,8% 27,3% 47,6% 53,7% 32,8% 1,2% 1,6% 10,2% 69,9% 15,2% 12,2% 15,0% 15,0% 14,2% 14,5% 33,6% 36,4% 23,4% 18,1% 18,1% 19,1% 0,0% 0																
Net horder Net horder Net bookings Net book																
PS NA 657.1% NA 336.8% 70.3% 10.2% 213.9% 150.9% 14.2% 14.5% 33.6% 36.4% 23.4% 18.1% 19.1% 28.4% 28.3% 81.4% 60.5% 23.4% 37.9% 46.1% 19.4% 1.1% 2.7% 10.0% 7.7% 14.5% 13.1% 28.4% 28.3% 81.4% 60.5% 23.4% 37.9% 46.1% 19.4% 1.1% 2.7% 10.0% 7.7% 14.5% 13.1% 28.4% 28.3% 18.1% 60.5% 23.4% 37.9% 46.1% 19.4% 1.1% 2.7% 10.0% 7.7% 14.5% 13.1% 28.4% 18.1																
19.1% (0.4%) (0.1%) 0.2% 0.9% 13.0% 3.5% 22.6% 22.1% 21.5% 8.6% 18.4% 0.9% 1.2% 13.1%																
## STIDIA	EPS															
Vernue Available Availab																
State Stat	EBITDA		28.4%	28.3%	81.4%	60.5%	23.4%	37.9%	46.1%	19.4%	1.1%	2.7%	10.0%	7.7%	14.5%	13.1%
rowth: core rowth: record records: record records: record	REVENUE ANALYSIS															
rowth: FX	Total revenue	\$ 437	\$ 579	\$ 652	\$ 185	\$ 204	\$ 208	\$ 214	\$ 810	\$ 214	\$ 220	\$ 226	\$ 232	\$ 891	\$ 1,000	\$ 1,106
30.4% 32.5% 32.5% 32.5% 32.5% 32.5% 32.5% 32.3% 27.9% 22.9% 22.6% 24.1% 15.7% 8.0% 8.7% 8.5% 10.7% 10.6% 8.7% 10.6% 8.7% 10.6% 8.7% 10.6% 10	Growth: core		4.3%	12.3%	22.6%	26.2%	22.7%	24.9%	24.1%	20.2%	12.8%	12.7%	10.8%	13.9%	12.2%	10.6%
Growth: total 32.5% 12.7% 23.3% 27.9% 22.9% 22.6% 24.1% 15.7% 8.0% 8.7% 8.5% 10.1% 12.2% 10.6% genining backlog Revenue (579) (652) (185) (204) (208) (214) (810) (214) (220) (226) (232) (286) (195) (1,000) (1,106)	Growth: FX		(2.2%)	0.4%	0.6%	1.2%	(0.2%)	(2.7%)	(0.4%)	(4.8%)	(4.8%)	(4.0%)	(2.3%)	(3.9%)	0.0%	
Growth: total 32.5% 12.7% 23.3% 27.9% 22.9% 22.6% 24.1% 15.7% 8.0% 8.7% 8.5% 10.1% 12.2% 10.6% genining backlog Revenue (579) (652) (185) (204) (208) (214) (810) (214) (220) (226) (232) (286) (195) (1,000) (1,106)	Growth: acquisitions		30.4%	0.0%	0.1%	0.4%	0.4%	0.4%	0.4%	0.3%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%
S 1,222 S 1,321 S 1,491 S 1,594 S 1,493 S 1,506 S 1,491 S 1,589 S 1,617 S 1,661 S 1,706 S 1,589 S 1,752 S 1,952 S																
Revenue (579) (652) (185) (204) (208) (214) (810) (214) (220) (226) (232) (891) (1,000) (1,106																
Net bookings Other adjustments 5																
Other adjustments ding backlog \$ 1,222 \$ 1,321 \$ 1,491 \$ 1,594 \$ 1,493 \$ 1,506 \$ 1,589 \$ 1,589 \$ 1,617 \$ 1,661 \$ 1,706 \$ 1,752 \$ 1,752 \$ 1,752 \$ 1,752 \$ 2,173 \$ 1,200																
acklog backlog s 1,222 s 1,321 s 1,491 s 1,594 s 1,493 s 1,506 s 1,589 s 1,589 s 1,517 s 1,661 s 1,706 s 1,752			6/6		281						264	2/1	278		1,200	1,327
at book-to-bill acklog burn rate			2												l 	
## April	Ending backlog	\$ 1,222	\$ 1,321	\$ 1,491	\$ 1,594	\$ 1,493	\$ 1,506	\$ 1,589	\$ 1,589	\$ 1,617	\$ 1,661	\$ 1,706	\$ 1,752	\$ 1,752	\$ 1,952	\$ 2,173
## April	Net book-to-bill		1.17	1.25	1.52	0.51	1.20	1.48	1.17	1.20	1.20	1.20	1.20	1.20	1.20	1.20
THER ash and equivalents ash and equivalents by the cash (debt) (513) (513) (513) (498) (475) (433) (403) (403) (294) (401) (4	Backlog burn rate															
ash and equivalents \$ 81																
obtail debt 594 594 599 589 588 420 420 420 401 381 362 362 284 258 Net cash (debt) ebt to TTM EBITDA 0.0 x 4.8x (475) \$ (433) \$ (433) \$ (294) \$ (294) \$ (301) \$ (273) \$ (232) \$ (226) \$ (26) \$ (99) \$ 22 each flow from operations apital expenditures \$ 43 \$ 37 \$ 31 \$ 49 \$ 37 \$ 14 \$ 131 \$ (0) \$ 35 \$ 49 \$ 13 \$ 98 \$ 158 \$ 152 Free cash flow \$ 33 \$ 20 \$ 27 \$ 41 \$ 32 \$ 6 \$ 106 \$ (7) \$ (\$ 81	\$ 97	\$ 114	\$ 156	\$ 186	\$ 126	\$ 126	\$ 110	\$ 128	\$ 150	\$ 136	\$ 136	\$ 185	\$ 280
Net cash (debt) \$ (513) \$ (498) \$ (475) \$ (433) \$ (403) \$ (294) \$ (294) \$ (294) \$ (301) \$ (273) \$ (232) \$ (226) \$ (226) \$ (99) \$ 22 expenditures apilital expenditures (10) \$ (31) \$ (213) \$ (213) \$ (213) \$ (213) \$ (226) \$ (214) \$ (215) \$ (216) \$ (
belt of TTM EBITDA 0.0x																
ash flow from operations apital expenditures Free cash flow \$ 43																
apital expenditures Free cash flow 10 (18) (5) (8) (5) (8) (5) (8) (26) (7) (7) (7) (7) (7) (28) (29) (30)																
Free cash flow \$ 33 \$ 20 \$ 27 \$ 41 \$ 32 \$ 6 \$ 106 \$ (7) \$ 28 \$ 42 \$ 6 \$ 70 \$ 129 \$ 122 addcount (actual) \$ 4,890 \$ 4,850 \$ 5 \$ 6 \$ 6 \$ 7 \$ 5,600 \$ 5,600 \$ 5,725 \$ 5,850 \$ 5,975 \$ 6,100 \$ 6,100 \$ 6,600 \$ 7,100 anglible book value per share \$ \$ (10)	Cash flow from operations		\$ 43	\$ 37	\$ 31	\$ 49	\$ 37	\$ 14	\$ 131	\$ (0)	\$ 35	\$ 49	\$ 13	\$ 98	\$ 158	\$ 152
eadcount (actual) 4,890 4,850 5,500 5,600 5,600 5,725 5,850 5,975 6,100 6,100 6,600 7,100 cook value per share \$ 6 \$ 5 \$ 5 \$ 6 \$ 6 \$ 7 \$ 7 \$ 7 \$ 7 \$ 7 \$ 7 \$ 7 \$ 7	Capital expenditures					(8)										
eadcount (actual) 4,890 4,850 5,500 5,600 5,600 5,725 5,850 5,975 6,100 6,100 6,600 7,100 cook value per share \$ 6 \$ 5 \$ 5 \$ 6 \$ 6 \$ 7 \$ 7 \$ 7 \$ 7 \$ 7 \$ 7 \$ 7 \$ 7	Free cash flow		\$ 33	\$ 20	\$ 27	\$ 41	\$ 32	\$ 6	\$ 106	\$ (7)	\$ 28	\$ 42	\$ 6	\$ 70	\$ 129	\$ 122
ook value per share \$ 6 \$ 5 \$ 5 \$ 6 \$ 6 \$ 7 \$ 7 \$ 7 \$ 7 \$ 7 \$ 7 \$ 9 \$ 10 angible book value per share \$ (10) \$ (10) \$ (10) \$ (9) \$ (9) \$ (6) \$ (7) \$ (5) \$ (5) \$ (4) \$ (4) \$ (4) \$ (2) \$ 0	Headcount (actual)		4 890	4 850			5 500	5 600	5 600	5 725	5.850	5 975	6 100	6 100	6,600	7 100
anglible book value per share \$ (10) \$ (10) \$ (10) \$ (9) \$ (9) \$ (6) \$ (7) \$ (5) \$ (5) \$ (4) \$ (4) \$ (2) \$ 0																
	Book value per share															
	Tangible book value per share	d Wolle Ford	\$ (10)	\$ (10)	\$ (10)	\$ (9)	\$ (9)	\$ (6)	\$ (7)	\$ (5)	\$ (5)	\$ (4)	\$ (4)	\$ (4)	\$ (2)	\$ 0

Source for all: Company reports and Wells Fargo Securities, LLC estimates

Company Description:

Raleigh, North Carolina-based INC Research Holdings, Inc. (NASDAQ: INCR) is a mid-size clinical contract research organization. The company is a pure play in clinical (phase I-IV) development. The company is differentiated by its specialization in trials related to central nervous system therapies. It operates in one segment.

Required Disclosures



0	Dat e 11 <i>/</i> 7/ 2014	Publication Price (\$)	RatingCode IPO at \$18.50	I	Val. Rng. Low	Val. Rng. High	I	Close Price(\$)
	12/2/2014		Evans					
•	12/2/2014	24.00	1		27.00	28.00		24.20
•	1/22/2015	25.50	1		29.00	30.00		24.58

Source: Wells Fargo Securities, LLC estimates and Reuters data



Additional Information Available Upon Request

I certify that:

- 1) All views expressed in this research report accurately reflect my personal views about any and all of the subject securities or issuers discussed; and
- 2) No part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by me in this research report.
- Wells Fargo Securities, LLC maintains a market in the common stock of INC Research Holdings, Inc.
- Wells Fargo Securities, LLC or its affiliates managed or comanaged a public offering of securities for INC Research Holdings, Inc. within the past 12 months.

- Wells Fargo Securities, LLC or its affiliates received compensation for investment banking services from INC Research Holdings, Inc. in the past 12 months.
- INC Research Holdings, Inc. currently is, or during the 12-month period preceding the date of distribution of the research report was, a client of Wells Fargo Securities, LLC. Wells Fargo Securities, LLC provided investment banking services to INC Research Holdings, Inc.
- Wells Fargo Securities, LLC or its affiliates intends to seek or expects to receive compensation for investment banking services in the next three months from an affiliate of INC Research Holdings, Inc.

INCR: Risks include: (1) project cancellations or delays due to client M&A, economic weakness, pipeline reprioritization, or compound failure; (2) a reversal in the trend toward increased outsourcing; (3) regulatory risks; (4) limited track record in public equity markets; and (5) controlled company status.

Wells Fargo Securities, LLC does not compensate its research analysts based on specific investment banking transactions. Wells Fargo Securities, LLC's research analysts receive compensation that is based upon and impacted by the overall profitability and revenue of the firm, which includes, but is not limited to investment banking revenue.

STOCK RATING

1=Outperform: The stock appears attractively valued, and we believe the stock's total return will exceed that of the market over the next 12 months. BUY

2=Market Perform: The stock appears appropriately valued, and we believe the stock's total return will be in line with the market over the next 12 months. HOLD

3=Underperform: The stock appears overvalued, and we believe the stock's total return will be below the market over the next 12 months. SELL

SECTOR RATING

O=Overweight: Industry expected to outperform the relevant broad market benchmark over the next 12 months.

M=Market Weight: Industry expected to perform in-line with the relevant broad market benchmark over the next 12 months.

U=Underweight: Industry expected to underperform the relevant broad market benchmark over the next 12 months.

VOLATILITY RATING

V = A stock is defined as volatile if the stock price has fluctuated by +/-20% or greater in at least 8 of the past 24 months or if the analyst expects significant volatility. All IPO stocks are automatically rated volatile within the first 24 months of trading.

As of: February 24, 2015

44% of companies covered by Wells Fargo Securities, LLC Equity Research are rated Outperform.	Wells Fargo Securities, LLC has provided investment banking services for 44% of its Equity Research Outperform-rated companies.
55% of companies covered by Wells Fargo Securities, LLC Equity Research are rated Market Perform.	Wells Fargo Securities, LLC has provided investment banking services for 30% of its Equity Research Market Perform-rated companies.
2% of companies covered by Wells Fargo Securities, LLC Equity Research are rated Underperform.	Wells Fargo Securities, LLC has provided investment banking services for 39% of its Equity Research Underperform-rated companies.

Important Disclosure for International Clients

EEA – The securities and related financial instruments described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. For recipients in the EEA, this report is distributed by Wells Fargo Securities International Limited ("WFSIL"). WFSIL is a U.K. incorporated investment firm authorized and regulated by the Financial Conduct Authority. For the purposes of Section 21 of the UK Financial Services and Markets Act 2000 ("the Act"), the content of this report has been approved by WFSIL a regulated person under the Act. WFSIL does not deal with retail clients as defined in the Markets in Financial Instruments Directive 2007. The FCA rules made under the Financial Services and Markets Act 2000 for the protection of retail clients will therefore not apply, nor will the Financial Services Compensation Scheme be available. This report is not intended for, and should not be relied upon by, retail clients.

Australia — Wells Fargo Securities, LLC is exempt from the requirements to hold an Australian financial services license in respect of the financial services it provides to wholesale clients in Australia. Wells Fargo Securities, LLC is regulated under U.S. laws which differ from Australian laws. Any offer or documentation provided to Australian recipients by Wells Fargo Securities, LLC in the course of providing the financial services will be prepared in accordance with the laws of the United States and not Australian laws.

Canada – This report is distributed in Canada by Wells Fargo Securities Canada, Ltd., a registered investment dealer in Canada and member of the Investment Industry Regulatory Organization of Canada (IIROC) and Canadian Investor Protection Fund (CIPF). This report has not been prepared subject to Canadian disclosure requirements.

Hong Kong – This report is issued and distributed in Hong Kong by Wells Fargo Securities Asia Limited ("WFSAL"), a Hong Kong incorporated investment firm licensed and regulated by the Securities and Futures Commission of Hong Kong ("the SFC") to carry on types 1, 4, 6 and 9 regulated activities (as defined in the Securities and Futures Ordinance (Cap. 571 of The Laws of Hong Kong), "the SFO"). This report is not intended for, and should not be relied on by, any person other than professional investors (as defined in the SFO). Any securities and related financial instruments described herein are not intended for sale, nor will be sold, to any person other than professional investors (as defined in the SFO). The author or authors of this report is or are not licensed by the SFC. Professional investors who receive this report should direct any queries regarding its contents to Mark Jones at WFSAL (email: wfsalresearch@wellsfargo.com).

Japan — This report is distributed in Japan by Wells Fargo Securities (Japan) Co., Ltd, registered with the Kanto Local Finance Bureau to conduct broking and dealing of type 1 and type 2 financial instruments and agency or intermediary service for entry into investment advisory or discretionary investment contracts. This report is intended for distribution only to professional investors (Tokutei Toushika) and is not intended for, and should not be relied upon by, ordinary customers (Ippan Toushika).

The ratings stated on the document are not provided by rating agencies registered with the Financial Services Agency of Japan (JFSA) but by group companies of JFSA-registered rating agencies. These group companies may include Moody's Investors Services Inc., Standard & Poor's Rating Services and/or Fitch Ratings. Any decisions to invest in securities or transactions should be made after reviewing policies and methodologies used for assigning credit ratings and assumptions, significance and limitations of the credit ratings stated on the respective rating agencies' websites.

About Wells Fargo Securities

Wells Fargo Securities is the trade name for the capital markets and investment banking services of Wells Fargo & Company and its subsidiaries, including but not limited to Wells Fargo Securities, LLC, a U.S. broker-dealer registered with the U.S. Securities and Exchange Commission and a member of NYSE, FINRA, NFA and SIPC, Wells Fargo Institutional Securities, LLC, a member of FINRA and SIPC, Wells Fargo Prime Services, LLC, a member of FINRA, NFA and SIPC, Wells Fargo Securities Canada, Ltd., a member of IIROC and CIPF, Wells Fargo Bank, N.A. and Wells Fargo Securities International Limited, authorized and regulated by the Financial Conduct Authority.

This report is for your information only and is not an offer to sell, or a solicitation of an offer to buy, the securities or instruments named or described in this report. Interested parties are advised to contact the entity with which they deal, or the entity that provided this report to them, if they desire further information. The information in this report has been obtained or derived from sources believed by Wells Fargo Securities, LLC, to be reliable, but Wells Fargo Securities, LLC does not represent that this information is accurate or complete. Any opinions or estimates contained in this report represent the judgment of Wells Fargo Securities, LLC, at this time, and are subject to change without notice. For the purposes of the U.K. Financial Conduct Authority's rules, this report constitutes impartial investment research. Each of Wells Fargo Securities, LLC and Wells Fargo Securities International Limited is a separate legal entity and distinct from affiliated banks. Copyright © 2015 Wells Fargo Securities, LLC.

SECURITIES: NOT FDIC-INSURED/NOT BANK-GUARANTEED/MAY LOSE VALUE